This editorial refers to 'High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study' † , by K. Matsushita et al., on page 2412.
quality of life, functional status, alleviate symptoms, and reduce mortality. The asymmetry between the recognition of PAD and the ability to offer meaningful treatments to patients suggests that tools that aid in the early identification of patients with or at risk of PAD may support efforts toward preventive, medical, and, when appropriate, interventional treatment strategies. To this end, there has been escalating interest in the potential role of cardiovascular biomarkers to improve the identification of patients with PAD.
In this issue of the European Heart Journal, Matsushita and colleagues present their study exploring the utility of high-sensitivity cardiac troponin (hs-cTnT) and N-terminal pro-brain natriuretic peptide (NT-proBNP) as predictors of incident PAD and critical limb ischaemia (CLI). 7 These candidate biomarkers, which have demonstrated utility in predicting cardiovascular risk in stable settings and beyond the coronary bed in prior studies, were evaluated in a diverse cohort of 12 288 patients without prevalent PAD from the Atherosclerotic Risk in Communities (ARIC) Study. [8] [9] [10] The mean age of study patients was nearly 57 years, 55.7% were women, and 24.7% were black patients. The hs-cTnT and NT-proBNP levels were measured using prospectively collected serum samples, and clinical PAD and CLI were identified using previously validated ICD-9 discharge codes. The association between each cardiac biomarker with incident PAD and CLI was quantified according to five assay level categories, and adjusted for potential confounders using three different models incorporating cardiovascular risk factors. An independent dose-response association of hs-cTnT and NT-proBNP with incident PAD was discovered, with an approximately eight-fold higher risk among patients in the highest biomarker level groups (corresponding to the 99th percentile of healthy subjects) with consistently higher hazard ratios for NT-proBNP compared with hs-cTnT. Among patients who were identified as having CLI, the highest category of hs-cTnT was associated with 24-fold risk, and NT-proBNP was associated with a 10-fold risk of CLI. Overall, both biomarkers were found to be more strongly correlated with CLI than PAD without CLI. The analysis was then repeated with stratification by demographic and clinical subgroups of particular interest, demonstrating consistent associations between biomarker levels and incident disease. Overall, this is a rigorously conducted observational study, using prospectively collected serum samples from a large historical cohort identifying significant associations between hs-cTnT and NT-proBNP levels and incident PAD and CLI. Among patients in the highest category of biomarker levels, after adjustment for some demographic factors, the association with incident disease was very strong. However, it should be noted that incorporating an adjustment model accounting for many traditional cardiovascular risk factors attenuated the final magnitude of association. Additionally, while the authors should be commended for formally evaluating the incremental change in risk discrimination utilizing these biomarkers, despite the strong association between hs-cTnT and CLI, hs-cTnT was unable to improve risk discrimination of CLI, and NT pro-BNP or both biomarkers together moved the needle only slightly. No combination of biomarkers led to significant changes in discrimination for PAD. This is likely because a model comprised of standard cardiovascular risk factors has relatively good discrimination for PAD and CLI, as evidenced by the high baseline c-statistic. In the context of clinical practice, broad application of these biomarkers for risk prediction will likely require additional validation in external data sets to determine their full potential. As with many other biomarkers, whether utilizing them to guide therapy can ultimately improve clinical outcomes or reduce incident PAD or CLI will require additional study.
Matsushita and colleagues have shed light upon an emerging and particularly suitable arena for biomarker research with this important study. Early identification of PAD and subsequent treatment may in fact have the potential to improve quality of life, reduce devastating morbidities such as major limb-related events, and extend longevity. After a period of relative quiescence, novel therapies for PAD are again emerging. In the COMPASS (Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease) study, a large multicenter, randomized placebo-controlled trial comparing combination low-dose rivaroxaban and aspirin with aspirin alone for prevention of cardiovascular events among patients with coronary artery disease or PAD on optimal medical therapy, among 7470 with PAD, combination therapy reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke by 28%, and reduced major adverse limb events including amputation by 46%, without a significant increase in fatal or critical organ bleeding. 11 In a substudy of the
PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a
Background of Aspirin -Thrombolysis in Myocardial Infarction 54) study evaluating long-term use of ticagrelor in patients with prior myocardial infarction, placebo-treated patients with PAD experienced a 1.6 times greater likelihood of major adverse cardiovascular events.
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Among the 1143 patients with known PAD in the study, ticagrelor in addition to aspirin reduced the risk of major adverse limb events by 35%, and achieved greater absolute risk reduction of major adverse cardiovascular events compared with those without PAD. Finally, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolucumab was shown in the FOURIER (Further Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial to markedly reduce low-density lipoprotein cholesterol and cardiovascular events in patients with atherosclerotic disease on a background of moderate-or high-intensity statin therapy. Among 3542 patients in the study with PAD and no history of myocardial infarction or stroke, evolocumab reduced the composite cardiovascular endpoint with greater absolute risk reduction among patients with PAD and additionally reduced the risk of major adverse limb events in all patients. 13 These studies underscore PAD as a modifiable disease process, and should serve as encouragement that identifying patients, using all the tools at our disposal, could have great impact. Biomarkers have been used widely across cardiovascular medicine to aid in diagnosis, inform risk models, and alter pharmacotherapuetic and procedural choices. Yet, biomarkers exist in various states of maturity in different disciplines (Take home figure) . While one can no longer imagine triaging coronary disease patients without using cardiac troponins, biomarkers in PAD remain largely exploratory at this time. Whether biomarkers in PAD are simply risk markers or may serve as modifiable surrogate endpoints remains to be seen. Deciding whether a biomarker should be directly targeted likely depends to an extent on whether it is on the causal pathway to disease. For example, while hs-CRP has been linked to vascular risk, a causal role in atherogenesis is yet unproven. Still, in the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) study, hs-CRP was used to identify patients for treatment with the fully humanized antibody canakinumab, which targets IL-1B, the product of the macrophage NLRP3 inflammasome, a receptor of the immune system through which LDL is linked to atherogenesis. 14, 15 Certainly, strategies that lower troponin and BNP levels may reduce all sorts of cardiovascular endpoints, including PAD-related ones, but further studies will need to establish what role these and other more comprehensive biomarker panels may have not only in more precise risk prognostication, but in altering therapies. With this study, Matsushita and colleagues have laid the foundation for this essential future work. Finally, we must comment on the senior author of this paper, the late Dr Alan T. Hirsch, a pioneer in the world of PAD. In one of the marvels of academic life, this paper will live on and help commemorate his immense contributions to the field and his enduring legacy.
